Liquid formulations for treatment of diseases or conditions
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61F-002/00
A01N-043/62
A61K-031/55
A61K-038/13
출원번호
US-0778872
(2010-05-12)
등록번호
US-8367097
(2013-02-05)
발명자
/ 주소
Mudumba, Sreenivasu
Dor, Philippe J M
Nivaggioli, Thierry
Weber, David A.
Farooq, Sidiq
출원인 / 주소
Santen Pharmaceutical Co., Ltd.
인용정보
피인용 횟수 :
5인용 특허 :
136
초록▼
Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are liquid formulations which del
Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; non-dispersed mass-forming liquid formulations which form a gel or gel-like substance in an aqueous medium; liquid formulations, comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration, or placement proximate to a site of a disease or condition to be treated in a subject. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration, or wet age-related macular degeneration in a subject. The liquid formulations may comprise rapamycin or other therapeutic agents.
대표청구항▼
1. A method for treating uveitis in a human subject, the method comprising administering to the human subject by intravitreal injection a volume of a liquid formulation comprising an effective amount of a therapeutic agent to treat uveitis in the human subject for at least two months,wherein the liq
1. A method for treating uveitis in a human subject, the method comprising administering to the human subject by intravitreal injection a volume of a liquid formulation comprising an effective amount of a therapeutic agent to treat uveitis in the human subject for at least two months,wherein the liquid formulation comprises the therapeutic agent, polyethylene glycol and ethanol,wherein the therapeutic agent is selected from the group consisting of rapamycin, and pharmaceutically acceptable salts thereof,wherein the liquid formulation is a liquid solution that forms a non-dispersed mass when injected into the vitreous, andwherein the therapeutic agent comprises between 0.5% to 6.0% of the total weight of the liquid formulation, and the polyethylene glycol comprises between 80% to 99% of the total weight of the liquid formulation. 2. The method of claim 1, wherein the polyethylene glycol and the ethanol diffuse out of the non-dispersed mass upon said injection leaving a precipitate of the therapeutic agent. 3. The method of claim 1, wherein the non-dispersed mass does not form a gel or gel-like substance upon injection. 4. The method of claim 1, wherein the liquid formulation has a viscosity of between 40 and 120 centipoise. 5. The method of claim 1, wherein the liquid formulation as a viscosity of between 60 and 80 centipoise. 6. The method of claim 1, wherein the therapeutic agent is rapamycin. 7. The method of claim 1, wherein the uveitis is chronic uveitis. 8. The method of claim 6, wherein the liquid formulation comprises about 2% (w/w) rapamycin, about 94% (w/w) PEG 400, and about 4% (w/w) ethanol. 9. The method of claim 6, wherein the volume of liquid formulation contains between 20 μg to 2 mg rapamycin. 10. The method of claim 1, wherein the therapeutic agent comprises between 0.628% to 5.233% of the total weight of the liquid formulation. 11. The method of claim 1, wherein the therapeutic agent comprises between 1% to 5% of the total weight of the liquid formulation. 12. The method of claim 1, wherein the polyethylene glycol is PEG 300 or PEG 400. 13. The method of claim 1, wherein the polyethylene glycol is PEG 400. 14. The method of claim 1, comprises administering to the human subject by intravitreal injection a volume of a liquid formulation comprising an effective amount of a therapeutic agent to treat uveitis in the human subject for two to three months.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (136)
Zhang,Mingqiang; Sheridan,Rose Mary, 39-desmethoxyrapamycin, compositions and methods of use thereof.
Osbakken, Robert S.; Hale, Mary Anne; Leivo, Frederick T.; Munk, James D., Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis.
Osbakken,Robert S.; Hale,Mary Anne; Leivo,Frederick T.; Munk,James D., Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis.
Peyman Gholam A. (New Orleans LA) Yang Dachuan (New Orleans LA) Khoobehi Bahram (New Orleans LA), Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same.
Appel, Leah E.; Curatolo, William J.; Herbig, Scott M.; Nightingale, James A. S.; Thombre, Avinash G., Controlled release by extrusion of solid amorphous dispersions of drugs.
Goulet Mark (Westfield NJ) Beattie Thomas R. (Scotch Plains NJ) Wyvratt Matthew J. (Mountainside NJ), Fluoromacrolides having immunosuppressive activity.
Armistead David A. (Maynard) Boger Joshua S. (Concord) Meyers Harold V. (Lexington) Saunders Jeffrey O. (Littleton) Tung Roger D. (Cambridge MA), Immunosuppressive compounds.
Gregory, Susan A; Isakson, Peter C; Anderson, Gary, Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor, a leukotriene B4 receptor inhibitor and a cyclosporin.
Steiner Joseph P. (Hampstead MD) Snyder Solomon (Baltimore MD) Hamilton Gregory S. (Catonsville MD), Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth.
Wright,Carol; Llanos,Gerard H.; Rakos,Ronald; King,Kristin; Falotico,Robert, Local delivery of rapamycin for treatment of proliferative sequelae associated with PTCA procedures, including delivery using a modified stent.
Luly Jay R. (Libertyville IL) Kawai Megumi (Libertyville IL) Or Yat S. (Libertyville IL) Wiedeman Paul (Libertyville IL) Wagner Rolf (Gurnee IL), Macrocyclic immunomodulators.
Calne Roy (22 Arrow Road Cambridge GB2 CB22AS), Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof.
Goulet Mark (Westfield NJ) Parsons William H. (Edison NJ) Sinclair Peter J. (Highland Park NJ) Wong Frederick (Glen Ridge NJ) Wyvratt Matthew J. (Mountainside NJ), O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives.
Goulet Mark (Westfield NJ) Parsons William H. (Edison NJ) Organ Helen M. (Fanwood NJ) Sinclair Peter J. (Highland Park NJ) Wong Frederick (Glen Ridge NJ) Wyvratt Matthew J. (Mountainside NJ), O-aryl,O-alkyl, and O-alkenyl-macrolides having immunosuppressive activity.
Robinson, Michael R.; Csaky, Karl G.; Yuan, Peng; Sung, Cynthia; Nussenblatt, Robert B.; Smith, Janine A., Ocular therapeutic agent delivery devices and methods for making and using such devices.
Gerhard Zenke DE; Hendrik Schuurman CH; Barbara Haeberlin CH; Armin Meinzer DE, Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin.
Smith ; III Amos B. (Merion PA) Condon Stephen M. (Philadelphia PA) Leazer ; Jr. Johnnie L. (Philadelphia PA) Maleczka Robert E. (Media PA) McCauley John A. (Philadelphia PA) Leahy James W. (San Lean, Processes and intermediates for preparing macrocycles.
Failli Amedeo A. (Princeton Junction NJ) Kao Wenling (Paoli PA) Steffan Robert J. (Langhorne PA) Vogel Robert L. (Stratford NJ), Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents.
Waranis Robert P. (Chazy NY) Harrison Maureen M. (St. Albans VT) Leonard Thomas W. (Plattsburgh NY) Enever Robin P. (Rouses Point NY), Rapamycin formulation for IV injection.
Harrison Maureen M. (St. Albans VT) Ofslager Christian L. (Plattsburgh NY) Waranis Robert P. (Chazy NY) Leonard Thomas W. (Wilmington NC), Rapamycin formulations for oral administration.
Weiner Alan L. (Cranbury NJ) Sinnett Kevin (Mukwonago WI) Johnson Sterling (Skillman NJ), Tack for intraocular drug delivery and method for inserting and removing same.
Dor, Philippe J. M.; Mudumba, Sreenivasu; Nivaggioli, Thierry; Weber, David A.; Farooq, Sidiq; Takhar, Sudeep, Formulations for treating ocular diseases and conditions.
Mudumba, Sreenivasu; Dor, Philippe J M; Nivaggioli, Thierry; Weber, David A.; Farooq, Sidiq, Liquid formulations for treatment of diseases or conditions.
Mudumba, Sreenivasu; Dor, Philippe J M; Nivaggioli, Thierry; Weber, David A.; Farooq, Sidiq, Liquid formulations for treatment of diseases or conditions.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.